VERU
VERU INC.
NASDAQ · Healthcare · Biotechnology · US
$2.41
+0.84%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.38
From 52W high−45.60%
Volume102836.00
Market cap$41.09M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.38
From 52W high
−45.60%
Volume
102836.00
Market cap
$41.09M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
42.9
MomentumView details →
1D Return
+0.84%
YTD Return
+12.38%
SummaryUpdated Jun 1, 2026
Veru Inc. (NASDAQ:VERU) is a Miami-based biopharmaceutical company that has undergone significant transformation since its founding in 1971. Originally established as The Female Health Company focused on women's health products, the company rebranded to Veru Inc. in 2017 to reflect its evolution into an oncology-focused drug development enterprise. Today, Veru operates as a clinical-stage biopharmaceutical company developing innovative treatments for cancer and other serious medical conditions, while maintaining a small commercial business in sexual health products.
Similar companies
Latest newsMore news →
Veru reported fiscal 2026 third quarter financial results and announced that its Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients.41d agoVeru announced that the U.S. Patent and Trademark Office issued a notice of allowance for a key methods-of-use patent covering enobosarm in combination with semaglutide for quality weight loss, with patent protection until at least October 2044.47d agoVeru Inc. announced full enrollment in its Phase 2b PLATEAU clinical trial evaluating enobosarm and semaglutide combination for weight loss.55d ago